Metformin and its Effects on Myocardial Dimension and Left ventricular hypertrophy in normotensive patients with Coronary Artery Disease. - The MET REMODEL Study

niversity of Dundee/NHS Tayside0 个研究点目标入组 68 人开始时间: 2014年10月15日最近更新: 2019年4月30日

适应症

试验速览

暂无简介。

•1) Participant is willing and able to give informed consent for participation in the study
•2) Aged 18 years or over
•3) Documented Ischaemic Heart Disease: either angio-graphically documented coronary artery disease or a previous history of myocardial infarction/angina.
•4) Have screening echocardiography based diagnosis of LVH based on ASE criteria (males >115g/m2, females >95g/m2)
•5) Fasting insulin resistance index = 2.7 at screening
•6) Clinic Blood pressure < 140/85 mm Hg or 24hr BP <135/85 daytime average in screening
•7)Able (in the Investigators opinion) and willing to comply with all study requirements.
•Are the trial subjects under 18? no
•Number of subjects for this age range: 0
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range 15
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range 39

•1) Severe cognitive impairment precluding written informed consent
•2) Type 1 or 2 Diabetes mellitus
•3) Chronic Heart Failure as evidenced by an echocardiogram or a diagnosis of CHF
•4) Left Ventricular Ejection Fraction <45% on echocardiography screening
•5) Contraindications to cardiac MRI (pacemakers, claustrophobia, metal implants, history of penetrative eye injury or exposure to metal fragments in eye requiring medical attention)
•6) Malignancy (receiving active treatment) or other life threatening diseases
•7) renal disease; CKD class 3B or worse (to exclude risk of lactic acidosis)
•8) Pregnancy and lactating women
•9) Any other considered by a study physician to be inappropriate for inclusion
•10) Participants who have participated in any other clinical trial within the previous 30 days will be excluded.

发起方

niversity of Dundee/NHS Tayside